Fig. (2).

A) Disease Activity Score in 28 joints (DAS28) (median and interquartile ranges) for patients with rheumatoid arthritis (RA) with infliximab (Ifx) trough levels (ITL) above and below the week 6 predictive cut-off. B) Patients (%) with low disease activity or remission (DAS28 < 3.2) at W54, according to the week 6 ITL cut-off. C) Kaplan-Meier curves for Ifx treatment survival, according to the week 6 predictive cut-off. Differences between groups were evaluated by the log- rank test. Mean survival time (mst).